Dry powder inhaler
Inventors
Kinsey, P. Spencer • Laurenzi, Brendan • Smutney, Chad C. • Adamo, Benoit • Guarneri, Joseph
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12508376-B2
Publication Date
2025-12-30
Expiration Date
Abstract
A dry powder inhaler including replaceable cartridges containing a dry powder for local or systemic delivery through the pulmonary tract and lungs is disclosed. The inhalers are used with inhalable dry powders, including medicament formulations comprising active agents for local or systemic delivery and for the treatment of diseases such as, pulmonary hypertension, cardiovascular disease, anaphylaxis, diabetes, obesity, cancer, and other diseases, or symptoms associated with these and other diseases, such as nausea, vomiting, pain and inflammation.
Core Innovation
The invention describes a breath-actuated dry powder inhaler system having a mouthpiece, a housing, and a rectangular body with a proximal end being substantially C-shaped. An enclosure is provided as a cartridge having a cup and a lid moveable relative to one another in translational motion, and the enclosure is configured to hold a dry powder composition.
The mouthpiece and the housing are movable relative to one another linearly, where the housing translationally glides over the body in a proximal to distal direction to open the inhaler, or from the distal to proximal direction to close the inhaler. The body and the housing are operably configured to engage by insertion to effectuate the enclosure to be reconfigured to attain an airflow pathway through the enclosure for discharging a powder dose upon inhalation.
The dry powder composition includes microcrystalline particles of 3,6-bis(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine made from surfactant-free solutions. Cannabidiol is adsorbed onto the microcrystalline particles in an amount from 10% to 40% (w/w), and the cartridge is configured to hold the dry powder composition for use with the breath-actuated dry powder inhaler as a reusable inhaler delivering a single unit dose.
Claims Coverage
The partial claim set includes two independent claims. Across these independent claims, the coverage centers on a breath-actuated dry powder inhaler with a linearly opening and closing cartridge enclosure that is reconfigured to create an airflow pathway for powder discharge, combined with a specific microcrystalline excipient and cannabidiol adsorbed from surfactant-free solutions in a defined weight range.
Breath-actuated dry powder inhaler with linearly reconfigurable cartridge airflow pathway
A breath-actuated dry powder inhaler comprising a mouthpiece, a housing, and a rectangular body having a proximal end being substantially C-shaped, with an enclosure cartridge having a cup and a lid moveable relative to one another in translational motion; the mouthpiece and housing movable linearly so the housing translationally glides over the body to open or close the inhaler; and the body and housing engage by insertion to effectuate the enclosure to be reconfigured to attain an airflow pathway through the enclosure for discharging a powder dose upon inhalation.
Microcrystalline 3,6-bis(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine with cannabidiol adsorbed in a defined weight range from surfactant-free solutions
A dry powder composition comprising microcrystalline particles of 3,6-bis(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine made from surfactant-free solutions, wherein cannabidiol is adsorbed onto the microcrystalline particles in an amount from 10% to 40% (w/w), and the enclosure is configured to hold the dry powder composition.
Reusable single unit dose configuration of the breath-actuated inhaler with reconfigured airflow pathway
The breath-actuated, dry powder inhaler is provided as a reusable inhaler for delivering a single unit dose of the dry powder pharmaceutical composition, wherein the housing translationally glides to open or close the inhaler and the enclosure is reconfigured to attain an airflow pathway through the enclosure for discharging a powder dose upon inhalation.
The independent claims jointly cover a breath-actuated dry powder inhaler architecture that uses linear relative motion to open and close a cartridge enclosure and reconfigure it to create an airflow pathway for discharging an inhaled dose, combined with a specified dry powder composition of surfactant-free microcrystalline 3,6-bis(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine having cannabidiol adsorbed at 10% to 40% (w/w).
Stated Advantages
Documented Applications
No documented applications found
Interested in licensing this patent?